Patents by Inventor Soren Aasmul
Soren Aasmul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240358250Abstract: The technology relates to video laryngoscopes with improved illumination. An example laryngoscope includes a display; a handle; an arm extending distally from the handle; a camera positioned at a distal end of the arm; a light source positioned at the distal end of the arm; and a unibody plug positioned at the distal end of the arm, the unibody plug. The unibody plug includes a light guide formed of a solid transparent material having an entry surface at a proximal end of the light guide and an exit surface at a distal end of the light guide, wherein the entry surface is adjacent the light source; and a frame that defines an air gap around at least 70% of a length of the light guide.Type: ApplicationFiled: April 1, 2024Publication date: October 31, 2024Applicant: Covidien LPInventors: Juergen Van Vlem, Yik Loong Tham, Soren Aasmul
-
Publication number: 20240252068Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: ApplicationFiled: March 19, 2024Publication date: August 1, 2024Inventors: Rajiv V. Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
-
Patent number: 11931145Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: GrantFiled: December 6, 2021Date of Patent: March 19, 2024Assignee: MEDTRONIC MINIMED, INC.Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
-
Publication number: 20220087578Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: ApplicationFiled: December 6, 2021Publication date: March 24, 2022Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
-
Patent number: 11229384Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: GrantFiled: November 29, 2018Date of Patent: January 25, 2022Assignee: MEDTRONIC MINIMED, INC.Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
-
Patent number: 10864286Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.Type: GrantFiled: December 19, 2019Date of Patent: December 15, 2020Assignee: Medtronic MiniMed, Inc.Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
-
Patent number: 10792378Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.Type: GrantFiled: April 28, 2017Date of Patent: October 6, 2020Assignee: Medtronics MiniMed, Inc.Inventors: Soren Aasmul, Jesper Svenning Kristensen
-
Publication number: 20200171173Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.Type: ApplicationFiled: December 19, 2019Publication date: June 4, 2020Applicant: Medtronic MIniMed, Inc.Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
-
Patent number: 10543288Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.Type: GrantFiled: April 28, 2017Date of Patent: January 28, 2020Assignee: MEDTRONIC MINIMED, INC.Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
-
Publication number: 20190246926Abstract: The invention relates to a device for detecting atrial fibrillation of a subject, comprising a member comprising —mechanical connection means to wearably connect the member to a subject; —the member further comprising an optical sensor arranged to measure a signal representing a blood perfusion parameter of the subject; the member comprising the optical sensor and mechanical connection means at such relative positions that when the mechanical connection means connect the member to the subject, the optica! sensor operatively faces the subject. The device is arranged to detect atrial fibrillation of the subject based on the signal measured by the optical sensor.Type: ApplicationFiled: June 22, 2017Publication date: August 15, 2019Inventors: Nathalie Virag, Soren Aasmul, Catherine Chassard, Richard Cornelussen, Gerard Hill, Robert Leinders, Mirko De Melis, Raphael Schneider, Vasiliki Spyropoulou
-
Publication number: 20190117137Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: ApplicationFiled: November 29, 2018Publication date: April 25, 2019Inventors: RAJIV SHAH, JESPER SVENNING KRISTENSEN, KATHERINE T. WOLFE, SOREN AASMUL, ANUBHUTI BANSAL
-
Patent number: 10194845Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: GrantFiled: March 30, 2017Date of Patent: February 5, 2019Assignee: MEDTRONIC MINIMED, INC.Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
-
Publication number: 20180311383Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.Type: ApplicationFiled: April 28, 2017Publication date: November 1, 2018Applicant: Medtronic MiniMed, Inc.Inventors: Soren Aasmul, Jesper Svenning Kristensen
-
Publication number: 20180311382Abstract: The invention is directed to a competitive glucose binding affinity assay comprising a glucose receptor (typically mannan binding lectin) labeled with an assay fluorophore and a modified glucose analog (typically dextran) labeled with a reference fluorophore. In certain embodiments, the glucose analog is dextran and is coupled to both a reference fluorophore and a quencher dye (e.g. hexamethoxy crystalviolet-1). Optionally the reference fluorophore is blue shifted relative to the assay fluorophore.Type: ApplicationFiled: April 28, 2017Publication date: November 1, 2018Applicant: Medtronic MiniMed, Inc.Inventors: Tri T. Dang, Soren Aasmul, Jesper Svenning Kristensen, Joseph Hanna, Robert McKinlay
-
Patent number: 9936905Abstract: A device for detection or measurement of a carbohydrate analyte in fluid comprises: an optical sensor comprising components of an assay for carbohydrate analyte, the readout of which is a detectable or measurable optical signal, and a light guide having a distal portion optically coupled to the assay components and a proximal portion; and a reader for interrogating the optical sensor, the reader comprising an assay interrogating system including a lens; and an interface portion forming part of at least one of the optical sensor and the reader, the interface portion being capable of removably constraining the proximal portion of the light guide and the lens of the assay interrogating system in an optically coupled arrangement. The device may be combined with an insulin-infusion system.Type: GrantFiled: October 13, 2014Date of Patent: April 10, 2018Assignee: Medtronic MiniMed, Inc.Inventors: Eric Allan Larson, Voltaire Isaac Lebron, Kevin Holz, Jasson Rodriguez, Ameya Kantak, Soren Aasmul
-
Patent number: 9848805Abstract: A new biostable glucose permeable polymer has been developed which is useful, for example, in implantable glucose sensors. This biostable glucose permeable polymer has a number of advantageous characteristics and, for example, does not undergo hydrolytic cleavage and degradation, thereby providing a composition that facilitates long term sensor stability in vivo. The versatile characteristics of this polymer allow it to be used in a variety of contexts, for example to form the body of an implantable glucose sensor. The invention includes the polymer composition, sensor systems formed from this polymer composition, and methods for making and using such sensor systems.Type: GrantFiled: December 18, 2015Date of Patent: December 26, 2017Assignee: Medtronic MiniMed, Inc.Inventors: Tri T. Dang, Henrik Egesborg, Jakob Janting, Rajiv Shah, Daniel Aaskov, Joseph F. Hall, Soren Aasmul
-
Publication number: 20170215775Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: ApplicationFiled: March 30, 2017Publication date: August 3, 2017Inventors: RAJIV SHAH, JESPER SVENNING KRISTENSEN, KATHERINE T. WOLFE, SOREN AASMUL, ANUBHUTI BANSAL
-
Publication number: 20170172471Abstract: A new biostable glucose permeable polymer has been developed which is useful, for example, in implantable glucose sensors. This biostable glucose permeable polymer has a number of advantageous characteristics and, for example, does not undergo hydrolytic cleavage and degradation, thereby providing a composition that facilitates long term sensor stability in vivo. The versatile characteristics of this polymer allow it to be used in a variety of contexts, for example to form the body of an implantable glucose sensor. The invention includes the polymer composition, sensor systems formed from this polymer composition, and methods for making and using such sensor systems.Type: ApplicationFiled: December 18, 2015Publication date: June 22, 2017Applicant: Medtronic MiniMed, Inc.Inventors: Tri T. Dang, Henrik Egesborg, Jakob Janting, Rajiv Shah, Daniel Aaskov, Joseph F. Hall, Soren Aasmul
-
Patent number: 9642568Abstract: A continuous glucose monitoring system may include a hand-held monitor, a transmitter, an insulin pump, and an orthogonally redundant glucose sensor, which may comprise an optical glucose sensor and a non-optical glucose sensor. The former may be a fiber optical sensor, including a competitive glucose binding affinity assay with a glucose analog and a fluorophore-labeled glucose receptor, which is interrogated by an optical interrogating system, e.g., a stacked planar integrated optical system. The non-optical sensor may be an electrochemical sensor having a plurality of electrodes distributed along the length thereof. Proximal portions of the optical and electrochemical sensors may be housed inside the transmitter and operationally coupled with instrumentation for, e.g., receiving signals from the sensors, converting to respective glucose values, and communicating the glucose values.Type: GrantFiled: May 23, 2012Date of Patent: May 9, 2017Assignee: MEDTRONIC MINIMED, INC.Inventors: Rajiv Shah, Jesper Svenning Kristensen, Katherine T. Wolfe, Soren Aasmul, Anubhuti Bansal
-
Patent number: 9421287Abstract: Medical devices are typically sterilized in processes used to manufacture such products and their sterilization by exposure to radiation is a common practice. Radiation has a number of advantages over other sterilization processes including a high penetrating ability, relatively low chemical reactivity, and instantaneous effects without the need to control temperature, pressure, vacuum, or humidity. Unfortunately, radiation sterilization can compromise the function of certain components of medical devices. For example, radiation sterilization can lead to loss of protein activity and/or lead to bleaching of various dye compounds. Embodiments of the invention provide methods and materials that can be used to protect medical devices from unwanted effects of radiation sterilization.Type: GrantFiled: March 5, 2015Date of Patent: August 23, 2016Assignee: Medtronic Minimed, Inc.Inventors: Jesper Svenning Kristensen, Soren Aasmul